Adjuvant Immune Checkpoint Inhibitor Versus Observation After Neoadjuvant Immunochemotherapy and Surgery in High-Risk NSCLC
NCT07748325
·
clinicaltrials.gov ↗
PHASE2
Phase
RECRUITING
Status
100
Enrollment
OTHER
Sponsor class
Conditions
Non-Small Cell Lung Cancer
Adjuvant Therapy
Immune Checkpoint Inhibitors
Interventions
DRUG:
Sintilimab
Sponsor
Sichuan University